Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +36.87%
#3 Cysic Cysic +15.83%
#4 Fabric Protocol Fabric Protocol +12.01%
#5 Bedrock Bedrock +9.08%
#6 Cap Cap +8.32%
#7 stake.link stake.link +6.45%
#8 Pons Pons +5.85%
#9 Enso Enso +5.58%
#10 DUSK Network DUSK Network +4.98%
Coin of the day
EXOD EXOD
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Pascal Biosciences Inc. Pascal Biosciences Inc.

Pascal Biosciences Inc.

PSCBF
Classifica tra le azioni #37975
Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to... Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy. Furthermore, Pascal is progressing a specialized antibody therapy aimed at B-cells, intended for conditions like acute lymphoblastic leukemia and various B-cell lymphomas. The company is also investigating cannabinoid-derived products as potential treatments for COVID-19. To support its research, Pascal Biosciences maintains an exclusive licensing agreement with the University of Washington for a cannabinoid-based therapeutic against glioblastoma multiforme and brain metastases. It also benefits from a collaborative research partnership with SoRSE Technology Corporation, focused on advancing PAS-393 toward clinical trials. Founded in 2011, the company operates from its headquarters in Seattle, Washington.
Prezzo delle azioni
$0.1
Ultima sincronizzazione: 2024-06-18
Capitalizzazione di mercato
$1.31M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Pascal Biosciences Inc. (PSCBF)

Categoria

Healthcare
Ricavi di Pascal Biosciences Inc. (PSCBF)
Ricavi nel Feb 2024 TTM: $700.83K
Secondo gli ultimi rapporti finanziari di Pascal Biosciences Inc., i ricavi attuali dell'azienda (TTM) sono pari a $700.83K. Nel 2022, l'azienda ha registrato ricavi di 0.00 uguale a i ricavi dell'anno 2021, che erano pari a 0.00. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Pascal Biosciences Inc. da 2019 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) $700.83K 41.81%
2023 $494.20K 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 1,801,231.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 859,063.16%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 1,442,584.10%
BE